Newsfeeds - Spark Newswire

1 minute read

Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside

Today, 1:54 PM

Guggenheim starts coverage on Chinook Therapeutics Inc (NASDAQ:KDNY) with a Buy rating and a $43 price target, being ‘bullish’ on the immunoglobulin…

KDNY

1 minute read

Reported Late Tuesday Feb. 28, Travere Therapeutics Announces Pricing Of $200M Upsized Public Offering Of 8.275M Shares Of Common Stock At A Price Of $21/Share And 1.25M Pre-Funded Warrants

By Happy Mohamed

Today, 1:54 PM

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of

TVTX

17 minute read

Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights

Today, 1:54 PM

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

4 minute read

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 1:54 PM

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

AKAN

1 minute read

Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $46

By Benzinga Newsdesk

Today, 1:54 PM

Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $42 to $46.

TVTX

2 minute read

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

By Vandana Singh

Today, 1:54 PM

The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…

CSLLY

1 minute read

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

By Benzinga Newsdesk

Today, 1:54 PM

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.

TVTX

1 minute read

Travere Therapeutics FILSPARI New Drug Application For Type 1 – New Molecular Entity Was Approved On 02/17/2023

By Happy Mohamed

Today, 1:54 PM

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216403

TVTX

1 minute read

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $36 Price Target

By Benzinga Newsdesk

Today, 1:54 PM

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $36 price target.

TVTX

5 minute read

February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More

By Shanthi Rexaline

Today, 1:54 PM

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.

APLS